HC Wainwright Reiterates “Buy” Rating for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGRGet Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 435.71% from the company’s current price.

Several other brokerages also recently commented on VYGR. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Citigroup began coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective for the company. Leerink Partners started coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price on the stock. Wedbush initiated coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They issued an “outperform” rating and a $11.00 target price on the stock. Finally, Canaccord Genuity Group restated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $15.97.

Read Our Latest Stock Analysis on VYGR

Voyager Therapeutics Stock Down 0.5 %

NASDAQ VYGR opened at $5.60 on Monday. The firm has a market cap of $305.93 million, a P/E ratio of 7.89 and a beta of 0.93. The company’s 50 day moving average is $5.81 and its 200-day moving average is $6.58. Voyager Therapeutics has a 12-month low of $4.99 and a 12-month high of $10.66.

Voyager Therapeutics (NASDAQ:VYGRGet Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter in the previous year, the firm posted ($0.59) EPS. Equities analysts expect that Voyager Therapeutics will post -0.91 EPS for the current year.

Insider Buying and Selling

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders sold 10,778 shares of company stock worth $58,548. Corporate insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its position in Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after buying an additional 4,098 shares during the period. Intech Investment Management LLC bought a new position in Voyager Therapeutics during the 3rd quarter worth approximately $74,000. Hsbc Holdings PLC purchased a new position in Voyager Therapeutics in the 2nd quarter worth approximately $128,000. SG Americas Securities LLC lifted its position in Voyager Therapeutics by 86.7% in the fourth quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock valued at $131,000 after purchasing an additional 10,704 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $216,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

(Get Free Report)

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

Featured Stories

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.